On the Record · Horizon Therapeutics

Horizon Therapeutics acquisitions, on the record

The businesses Horizon Therapeutics bought and sold, as its annual reports describe them, with the cash it reported paying for acquisitions each year and every deal filing since 2016.

Deals its annual reports describe

Business	Deal	When	Value
Medical Need Europe AB, part of the Immedica Group (Immedica) Word for word“On October 27, 2020, we sold our rights to develop and commercialize RAVICTI ® and BUPHENYL ® in Japan to Medical Need Europe AB, part of the Immedica Group, or Immedica .” 10-K for 2020	divestiture	On October 27, 2020	—
Immedica Word for word“On December 28, 2018, we sold our rights to RAVICTI and AMMONAPS ® (known as BUPHENYL in the United States and Japan) outside of North America and Japan to Immedica.” 10-K for 2020	divestiture	On December 28, 2018	—
Curzion Pharmaceuticals, Inc. (Curzion) Word for word“On April 1, 2020, we acquired Curzion Pharmaceuticals, Inc., or Curzion, a privately held development-stage biopharma company, and its development-stage oral selective lysophosphatidic acid 1 receptor (LPAR1) antagonist, CZN001 (renamed HZN-825), for an upfront payment with additional payments contingent on the achievement of development and regulatory milestones.” 10-K for 2020	acquisition	On April 1, 2020	—
Cosette Pharmaceuticals, Inc. (MIGERGOT rights) Word for word“On June 28, 2019, we sold our rights to MIGERGOT to Cosette Pharmaceuticals, Inc., for an upfront payment and potential additional contingent consideration payments.” 10-K for 2020	divestiture	On June 28, 2019	—
Vectura Group plc (LODOTRA rights in Europe) Word for word“Effective January 1, 2019, we amended our license and supply agreements with Jagotec AG and Skyepharma AG, which are affiliates of Vectura Group plc, or Vectura.” 10-K for 2020	divestiture	Effective January 1, 2019	—
Clinigen Group plc (IMUKIN rights outside the United States, Canada and Japan) Word for word“On July 24, 2018, we sold the rights to IMUKIN ® in all territories outside of the United States, Canada and Japan to Clinigen Group plc, or Clinigen, for an upfront payment and a potential additional contingent consideration payment that was subsequently received in September 2019, or the IMUKIN sale.” 10-K for 2020	divestiture	On July 24, 2018	—
Viela Bio, Inc. (Viela) Word for word“On January 31, 2021, we entered into an Agreement and Plan of Merger with Viela Bio, Inc., or Viela, to acquire all of the issued and outstanding shares of Viela’s common stock for $53.00 per share in cash, which represents a fully diluted equity value of approximately $3.05 billion, or approximately $2.67 billion net of Viela’s cash and cash equivalents.” 10-K for 2020	agreed acquisition	On January 31, 2021	$53.00 per share in cash, which represents a fully diluted equity value of approximately $3.05 billion, or approximately $2.67 billion net of Viela’s cash and cash equivalents
biologic drug product manufacturing facility from EirGen Pharma Limited (EirGen), a subsidiary of OPKO Health, Inc., in Waterford, Ireland Word for word“In July 2021, we completed the purchase of a biologic drug product manufacturing facility from EirGen Pharma Limited, or EirGen, a subsidiary of OPKO Health, Inc., in Waterford, Ireland.” 10-K for 2021	acquisition	In July 2021	—
rights to RAVICTI and BUPHENYL in Japan, sold to Medical Need Europe AB (Immedica Group) Word for word“In October 2020, we sold our rights to develop and commercialize RAVICTI ® and BUPHENYL ® in Japan to Medical Need Europe AB, part of the Immedica Group, or Immedica .” 10-K for 2021	divestiture	In October 2020	—
rights to MIGERGOT, sold to Cosette Pharmaceuticals, Inc. Word for word“In June 2019, we sold our rights to MIGERGOT to Cosette Pharmaceuticals, Inc., for an upfront payment and potential additional contingent consideration payments.” 10-K for 2021	divestiture	In June 2019	for an upfront payment and potential additional contingent consideration payments
rights to LODOTRA in Europe, transferred to Vectura (Jagotec AG and Skyepharma AG) Word for word“Effective January 2019, we amended our license and supply agreements with Jagotec AG and Skyepharma AG, which are affiliates of Vectura Group plc, or Vectura.” 10-K for 2021	divestiture	Effective January 2019	—
drug product biologics manufacturing facility from EirGen Pharma Limited Word for word“In July 2021, we completed the purchase of a drug product biologics manufacturing facility from EirGen Pharma Limited, or EirGen, a subsidiary of OPKO Health, Inc., in Waterford, Ireland.” 10-K for 2022	acquisition	July 2021	—
Viela Bio, Inc. Word for word“In March 2021, we completed the acquisition of Viela Bio, Inc., or Viela, in which we acquired all of the issued and outstanding shares of Viela’s common stock.” 10-K for 2022	acquisition	March 2021	—
Medical Need Europe AB, part of the Immedica Group (rights to RAVICTI and BUPHENYL in Japan) Word for word“In October 2020, we sold our rights to develop and commercialize RAVICTI ® and BUPHENYL ® in Japan to Medical Need Europe AB, part of the Immedica Group, or Immedica .” 10-K for 2022	divestiture	October 2020	—
Curzion Pharmaceuticals, Inc. Word for word“In April 2020, we acquired Curzion Pharmaceuticals, Inc., or Curzion, a privately held development-stage biopharma company, and its development-stage oral selective lysophosphatidic acid 1 receptor (LPAR 1 ) antagonist, CZN001 (renamed HZN-825), for an upfront payment with additional payments contingent on the achievement of development and regulatory milestones.” 10-K for 2022	acquisition	April 2020	—

As filedReported in the company's financial data (XBRL), each linked to its filing
Fiscal year ended	Cash paid for acquisitions (net of cash acquired)	Goodwill from acquisitions
2016-12-31	$1.35 billion	—
2017-12-31	$167.2 million	—
2020-12-31	$262.3 million	—
2021-12-31	$2.84 billion	$662.7 million
2022-12-31	$3.1 million	—

Deal filings since 2016

2023-10-06 Form 8-K, Item 2.01: Completion of Acquisition or Disposition of Assets
2022-12-12 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
2021-03-15 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
2021-02-01 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
2019-12-18 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
2019-07-16 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
2019-05-22 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
2019-03-11 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
2019-02-28 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
2018-10-19 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
2018-09-20 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
2018-07-03 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
2017-10-23 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
2017-03-30 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
2016-10-25 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
2016-10-25 Form 8-K, Item 2.01: Completion of Acquisition or Disposition of Assets
2016-09-29 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
2016-09-13 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
2016-09-12 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
2016-09-08 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
2016-01-14 Form 8-K, Item 2.01: Completion of Acquisition or Disposition of Assets

Read from Horizon Therapeutics’s annual reports (10-K for 2022, 10-K for 2021, 10-K for 2020) and the financial data it files with the SEC, as of 2023-03-01. Every quotation is word for word from the filing linked beside it; how these pages are built and checked. The full record is in its company data sheet.